Anti-PCSK9 Drugs

Download the PDF

If you are concerned about the potential impact of the new biologic cholesterol medications (known as anti-PCSK9) it is important to get the facts about these new drugs and their potential impact on your drug plan.

New treatments, like REPATHA™ have recently entered the Canadian market, however they are only intended to be used by patients who are high risk for cardiovascular events. See an analysis of the potential impact to your plan and how prior authorization can ensure that only appropriate patients are reimbursed for treatment.

Download pdf to read more.

Brought to you by: Amgen